The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

Feature Details Company Milestones and 2025 Catalysts Across Gene Therapy and Ophthalmic ProgramsNEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with Dr.

Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat NPDR.